Carrie Stricker on Barriers to Adopting Triple Therapy

Video

Carrie Stricker, PhD, RN, from Abramson Cancer Center, on Barriers to Adopting Triple Therapy

Carrie Stricker, PhD, RN, Oncology Nurse Practitioner, Abramson Cancer Center, Clinical Assistant Professor, School of Nursing, Abramson Cancer Center of the University of Pennsylvania, discusses barriers to starting patients on a combination of a NK1 receptor antagonist with 5-HT3 receptor antagonist plus dexamethasone, which is currently the standard of care for patients receiving highly emetogenic anticancer therapies.

The largest barrier for this therapy has traditionally been costs. In recent years, this has become less of a concern as insurance reimbursement has begun synchronizing with guidelines. The out of pocket costs were the greatest concern for patients until the development of an intravenous formulation of the NK1 receptor antagonist aprepitant.

The intravenous form, known as fosaprepitant, was shown to be equivalent to the three-day oral form, and generally does not require copay for the patient. This new formulation of the NK1 agonist has helped to remove one of largest compliance barriers.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute